President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...

Alnylam Pharmaceuticals, Inc. has announced the U.S. Food and Drug Administration (FDA) approval of the supplemental new drug application (SNDA) for its RNAi therapeutic, Amvuttra® (vutrisiran). This ...

Research analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for Alnylam Pharmaceuticals in a ...

Alnylam Pharmaceuticals, Inc.’s ALNY share price has dipped by 10.08%, which has investors questioning if this is right time ...

Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

Amvuttra operates via RNA interference (RNAi), a groundbreaking technology that inhibits the production of the TTR protein in ...